Bittergourd standardized as anti-diabetic
doi:10.1038/nindia.2007.17 Published online 25 September 2007
The extract of Momordica charantia Linn. or bittergourd is well known for its anti-diabetic property. However, due to lack of standardization of these extracts, their efficacy remained questionable. A new study has now successfully standardised the extract for use1. Researchers reported the hypoglycaemic and anti-lipidemic activities of the extract in rat models.
The experiment found that the standard extract enhanced insulin secretion by the islets of Langerhans, reduced glycogenesis in liver tissue, increased peripheral glucose utilization as well as serum protein levels.
The researchers also report that its anti-hyperlipidemic effect could represent a protective mechanism against the development of atherosclerosis, especially in diabetic condition. They suggest that the extract is safe for oral consumption. They also contend it could be useful in the management of diabetes mellitus and other associated complications.
The authors of this work are from: Prin. K. M .Kundnani College of Pharm, Department of Pharmacology and Toxicology, Jote Joy Building, Rambhau Salgaonkar Marg, Cuffe Parade, Mumbai, India; Sinhgad Institute of Pharmaceutical Sciences, Sector No. 309/310, Kusgaon (Bk) Lonavala, Pune, India
- Fernandes, Nafisa P. C. et al. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complementary and Alternative Medicine doi: 10.1186/1472-6882-7-29 (2007).